Compass Pathways Plc’s shares plummeted after its psychedelic drug to treat a form of depression disappointed investors in a late-stage trial. The company said its psilocybin drug reduced depression ...

Positive data on depression treatment based on a drug related to the psychedelic DMT is breathing life into shares of biotechs working on psychedelic medicines, after years of disappointments. Just as ...

Neumora halted one trial of its depression drug navacaprant and paused a pair of late-stage studies as it tries to learn from a recent phase 3 failure. The KOASTAL-1 study, which read out in January, ...

A new study from Cancer, a medical journal from the American Cancer Society, has found that just one dose of psilocybin — the active ingredient in magic mushrooms — can help cancer patients with ...

An experimental depression drug that joined the Neurocrine Biosciences pipeline as part of a broader package from Takeda Pharmaceutical failed to meet the main goal of a mid-stage clinical trial. The ...